McDermott Will & Emery advised Innate Pharma on the expansion of its collaboration with Sanofi. Sanofi is licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization.
The McDermott team that advised Innate Pharma comprised:
· Emmanuelle Trombe, partner, Katya Ascher, Counsel, and Caroline Noyrez, associate, on Life Sciences aspects
· Frédéric Pradelles, partner, on Competition aspects
· Côme de Saint Vincent, Counsel, on tax aspects